A report commissioned by the United Kingdom government has found data to corroborate a widely held belief: R&D collaborations with British universities are expensive. Yet with such institutions performing world-class science--and tax breaks and funding schemes offsetting the upfront costs--Big Pharma is lining up to strike deals. Just ask Pfizer.
Just days ago, GlaxoSmithKline signed the first big deal with the Francis Crick Institute. And now a high-profile examination of the state of play of partnering in academic research circles, the Dowling Report, says Glaxo is the single largest collaborator with academia in the U.K., for any industry.
Autifony Therapeutics has returned to its investors for £8 million ($12 million) to fund a broadening of its R&D ambitions. The company, which spun out of GlaxoSmithKline with an age-related hearing loss program in 2011, is now going after schizophrenia.
Two recently-published market analyses paint a picture of a competitive but growing vaccines field through 2020, with the newest report from Tufts University stating the industry is on track to post $40 billion in annual sales in 5 years.
Pfizer will be closing a plant in India later this year. The announcement comes less than a week after Novartis announced that its Sandoz generics unit would close a plant in India at the end of 2016.
Pfizer intends a close one of its plants in India, a facility that has sat mostly idle for two years. But it is not as if Pfizer will be short on manufacturing capacity in the country. As soon as it completes its $15 billion deal to buy Hospira, it will get that company's massive manufacturing network there, including a brand-spanking-new plant in Vizag.
Pfizer debuted its Center of Excellence in Precision Medicine in Santiago, Chile, last week, bulking up in Latin America, not exactly a hot spot for pharma industry R&D.
The year's 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013's top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma's macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index.
Antidepressants have long been linked to an increased risk of birth defects, with companies fighting claims that the meds cause serious issues in newborns if women take the drugs during pregnancy. Now, a new study published in the British Medical Journal shows that only some of the drugs turn up risks of birth defects, dealing a spate of good news to companies making the products.
Pfizer CEO Ian Read has long maintained that the company's vaccines unit should expand beyond the superstar pneumococcal disease blocker Prevenar. In addition to several moves last year and into this year, the company continued that work this week with the announcement of a "pivotal" trial for a surgical site infection candidate.